INTRODUCTION AND OBJECTIVES:
In urothelial carcinoma, genetic alterations in multiple cell-cycle regulations genes are frequent, including key tumor suppressor genes like TP53 and RB1. Prior studies have shown that alterations of TP53 and RB1, analyzed through protein p53 and RB expression respectively have prognostic significance. The goal of this study was to evaluate the correlation between TP53 and RB1 genotypes and phenotypes.
METHODS: Tumor and matched germline DNA were analyzed using the MSK-IMPACT assay that detects alterations in 410 oncogenes and tumor suppressor genes, including TP53 and RB1. A correlation between TP53 and RB1 mutation status and protein expression was performed. Tissue microarrays (TMA) of urothelial carcinoma of the bladder were assessed for p53 and RB expression as a validation cohort.
RESULTS: Overall, 171 patients with a median age of 69.4 years (IQR: 61.7-71.5) were included. Clinical stage was non muscle invasive bladder cancer in 14 (8.2%) patients, muscle invasive bladder cancer in 148 (86.5%) and metastatic in 9 (5.3%). Genetic alterations of TP53 and RB1 were found in 93 (53.8%) and 66 (38.2%) patients respectively. Protein expression was assessed from full section in 65 (38%) patients and from TMA in 106 (62%). Strong and diffuse p53 expression strongly correlated with missense TP53 mutations (n¼43, 78.2%, p<0.0001). In addition, complete lack of p53 expression was seen in tumors harboring truncating TP53 mutations (n¼ 20, 58.8%, p<0.0001) . Similarly, loss of RB expression strongly correlated with the presence of RB1 mutations (n¼43, 86%, p<0.0001). Tumors with wildtype TP53 or RB exhibited variable p53 and RB expression. In cases with both invasive and non-invasive components (n¼24), similar patterns of p53 and RB expression were observed.
CONCLUSIONS: The most common pattern of p53 expression that correlated with the presence of TP53 mutations are strong and diffuse nuclear expression (missense mutation) and absence of nuclear expression (truncating mutation). RB1 mutations generally result in loss of RB expression. The concordant pattern of p53 and RB expression between invasive and non-invasive component within the same tumor indicate that alterations in these genes occur early in the development of urothelial carcinoma.
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GERMLINE DNA REPAIR SINGLE NUCLEOTIDE POLYMORPHISMS IN UROTHELIAL CANCER PATIENTS.
INTRODUCTION AND OBJECTIVES:
Single nucleotide polymorphisms (SNPs) in genes involved in carcinogenesis and cancer growth have been investigated for their prognostic value in several cancers, including urothelial (UC). Repair of DNA damage is a key process involved in development of chemotherapy-resistance. The role of germline DNA repair gene (DRG) SNPs in patients with UC has not been explored. We hypothesized that germline SNPs of DRGs could be enriched and potentially associated with outcomes in UC patients exposed to platinum agents.
METHODS: We examined a cohort of 53 UC patients (median age 67, 42 males) enrolled in our IRB-approved Precision Medicine program. Patients had histologically confirmed UC (43 bladder, 10 upper tract UC) and received treatment with platinum-based chemotherapy. We isolated germline DNA from blood lymphocytes or buccal swabs, and used whole exome sequencing (WES) to examine germline SNPs. As a reference for SNP frequencies we used the Exome Aggregation Consortium (ExAC) database, the largest randomly selected germline WES database in general population, also including cancer patients.
RESULTS: Twelve different DRG SNPs were identified in germline DNA samples from 53 patients, affecting genes involved in non-homologous end-joining (RECQL4, n¼18, 54.50%; POLQ, n¼2, 6%), nucleotide excision repair (ERCC6, n¼2, 6%; XPA, n¼1, 3%; CCNH, n¼1, 3%; POLK, n¼1, 3%), homologous recombination (RNF168, n¼1, 3%; RAD17, n¼1, 3%; POLE, n¼1, 3%), Fanconi anemia pathway (POLN, n¼1, 3%), mismatch repair (EXO1, n¼1, 3%) and mitochondrial DNA repair (POLG, n¼2, 6%). The frequency of rs11342077 of the DNA helicase RECQL4 was significantly higher in our cohort (18/53, 34%) compared to its frequency in the ExAC database (p<0.01). There was no significant difference in overall survival (OS) between patients with and without DRG SNPs (log-rank p¼0.46). There was no significant association between the most commonly identified SNP rs11342077 and OS among UC patients with DRG SNPs (log-rank p¼0.39). Overall, the presence of DRG SNPs in our cohort (33/53, 62.3%) occurred at a significantly higher frequency compared to the ExAC database (0.56%, Chisquare p<0.01).
CONCLUSIONS: Germline DRG SNPs are more common in UC compared to other cancers, and could play a role as potential biomarkers of response to UC treatment with DNA damaging agents. In addition, if confirmed in larger scale studies, heritable DRG SNPs could potentially be used for identifying patients who will achieve downstaging or complete pathologic response in the neoadjuvant setting. Therefore, it is essential to classify experimental animal models of bladder cancer based on molecular subtypes. In this study, we characterized N-methyl-N-nitrosourea (MNU)-induced bladder tumors in rats and ex vivo-cultured spheroids derived from them to determine their similarities to the luminal and basal subtypes observed in human cancers.
METHODS: Female Fisher 344 rats at age of 7 weeks received 4 intravesical doses of 1.5mg/kg MNU. By week 8, the MNU bladders displayed evidence of dysplasia and by week 16 small animal ultrasounds revealed papillary tumors with associated CIS, high grade non-invasive disease, or invasion into the lamina propria. In order to assess the subtype memberships of mature invasive tumors, rats were sacrificed at 30 weeks. Bladder tumors were evaluated by H&E staining and immunohistochemistry using antibodies against basal marker CK14 and luminal CK20. Ex-vivo culture of tumor cells was carried out using a spheroidal culture method. Partially digested tumor fragments were cultured in StemProâ medium. Viability of ex-vivo cultured cells was evaluated by Ki67 immunohistochemical staining and growth assay under microscope. Cultured cells were also tested by immnohistochestry using antibodies of CK14 and CK20.
RESULTS: By about 30 weeks after exposure to MNU, rats developed 5-10-mm, protruding tumors in their bladders. Immunohistochemistry revealed enrichment of CK14-stained cells in CIS lesions and invasive tumors compared to normal urothelium, while the number of CK20-stained cells declined. Papillary tumors had a mixed staining pattern with both CK14 and CK20 positive staining. Partially digested fragments of tumors formed clear spheroids 24 hours after digestion. Immunohistochemistry revealed CK14-positive cells comprised 88% of spheroids and CK20-positive cells less than 5%.
CONCLUSIONS: The results of the present study demonstrate a pre-clinical model of urothelial cancer associated with progression of papillary non-muscle invasive bladder tumors with associated CIS to invasive cancers. CIS, invasive tumors, and ex-vivo cultured spheroids had the appearance of a basal subtype membership, while papillary tumors from the same model had staining patterns consistent with the urobasal/luminal tumor subtype. METHODS: Tumor specimens, including primary bladder tumors and lymph node metastases, were collected from 29 bladder cancer patients having standard of care tumor resection, who also had consented to an IRB-approved protocol for TIL generation. The tissue was minced into fragments, placed in individual wells of a 24-well plate, and propagated in high dose IL-2 for four weeks. TIL were considered expanded if they propagated to fill ¼2 wells. The remaining tumor material was digested into a single cell suspension and frozen. TIL were phenotyped by flow cytometry and assessed for autologous tumor reactivity through co-culture with tumor digest and IFN-gamma ELISA.
RESULTS: Twenty-seven of 29 tumors were harvested from radical cystectomy patients. Urothelial cell bladder tumors were cultured from 23 patients, of whom 19 (83%) demonstrated TIL expansion. Among these were 9/12 with preceding chemotherapy and 10/11 which had been chemotherapy naive. Expanded TIL were predominantly CD3þ (median 63%, range 10-87%) with a median of 30% CD8þ T cells (range 5-70%). Eight of 15 tested samples (53%) contained TIL that secreted IFN-gamma in response to autologous tumor. Microbial contamination was observed in six specimens. All lymphatic (5/5 samples) tissue collected demonstrated TIL expansion.
CONCLUSIONS: The study establishes the practical first step towards an autologous TIL therapy process for therapeutic testing in patients with bladder cancer. Human bladder cancer tissue can be used to expand tumor-specific TIL in vitro. TIL were also able to be expanded from patients that received chemotherapy prior to tumor resection. Future efforts will explore the ability to further expand bladder TIL cultures to clinically meaningful numbers to develop novel ACT strategies for patients with this diagnosis.
